Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374917 · ClinicalTrials.gov registry record · Phase 1
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
A Phase 1 study of Parkinsons Disease (PD), sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 12
- Study locations
NCT03374917 is a Phase 1 study of Parkinsons Disease (PD) that has completed, run by AbbVie. The registered enrollment target is 20 participants, below the 118-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (83% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT03374917, a Phase 1 study of Parkinsons Disease (PD), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).
Conditions Studied
Interventions
- DRUG ABBV-951
Study Locations (12)
California
- Loma Linda University /ID# 165592 - Loma Linda
- Univ CA, Irvine Med Ctr /ID# 165594 - Orange
Kentucky
- University of Kentucky Chandler Medical Center /ID# 164407 - Lexington
- University of Louisville /ID# 164997 - Louisville
Ohio
- University of Cincinnati /ID# 165142 - Cincinnati
- Cleveland Clinic Foundation /ID# 164413 - Cleveland
Arizona
- Banner Sun Health Res Inst /ID# 165840 - Sun City
Florida
- Compass Research /ID# 167329 - Orlando
Kansas
- Univ Kansas Med Ctr /ID# 166280 - Kansas City
Missouri
- Washington University-School of Medicine /ID# 164412 - St Louis
New York
- NYU Langone Medical Center /ID# 164924 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2019-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374917
The ClinicalTrials.gov registry entry for NCT03374917 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (83% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which ABBV-951 is the first listed.
NCT03374917 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Kentucky, Ohio.
Frequently Asked Questions
What is clinical trial NCT03374917 about?
NCT03374917 is a clinical study titled "A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).
What is the current status of trial NCT03374917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-04-18. Estimated completion is 2019-03-04.
What conditions does trial NCT03374917 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
What interventions are being tested in trial NCT03374917?
The interventions under investigation include: ABBV-951 (DRUG).
Who is sponsoring clinical trial NCT03374917?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03374917 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.